Merck KGaA (OTCMKTS:MKGAF) Stock Price Down 6% – Time to Sell?

Merck KGaA (OTCMKTS:MKGAF) fell 6% during mid-day trading on Wednesday. The company traded as low as $154.1260 and last traded at $154.1260. 76 shares changed hands during trading, a decline of 88% from the average daily volume of 632 shares. The stock had previously closed at $163.94.

Merck KGaA Trading Down 6.0%

The business has a 50 day simple moving average of $161.08 and a two-hundred day simple moving average of $150.70. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27. The stock has a market cap of $19.92 billion, a price-to-earnings ratio of 23.53 and a beta of 0.96.

Institutional Trading of Merck KGaA

Hedge funds and other institutional investors have recently made changes to their positions in the stock. North Star Asset Management Inc. acquired a new stake in Merck KGaA in the second quarter valued at $1,411,000. MASTERINVEST Kapitalanlage GmbH acquired a new position in Merck KGaA during the 2nd quarter worth $4,896,000. Ames National Corp bought a new stake in shares of Merck KGaA in the 2nd quarter worth about $1,009,000. Elefante Mark B bought a new stake in shares of Merck KGaA in the 2nd quarter worth about $617,000. Finally, Pinnacle Holdings LLC acquired a new stake in shares of Merck KGaA in the 2nd quarter valued at about $1,487,000. Institutional investors own 0.10% of the company’s stock.

About Merck KGaA

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. Merck KGaA is separate from the U.S.-based Merck & Co, Inc, although the two companies share historical roots.

The company operates through three business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, chemicals and bioprocessing technologies used by pharmaceutical, biotechnology and academic customers.